CJL
ITCI

Cyrus J. Lawrence’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cyrus J. Lawrence’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,550
Closed -$296K – 178
2024
Q4 		$296K Hold
3,550
– – 0.06% 59
2024
Q3 		$259K Hold
3,550
– – 0.05% 62
2024
Q2 		$243K Hold
3,550
– – 0.05% 64
2024
Q1 		$245K Buy
+3,550
New +$244K 0.05% 65
2023
Q3 		$184K Hold
3,550
– – 0.05% 66
2023
Q2 		$224K Hold
3,550
– – 0.05% 62
2023
Q1 		$192K Hold
3,550
– – 0.06% 66
2022
Q4 		$188K Hold
3,550
– – 0.06% 72
2022
Q3 		$165K Hold
3,550
– – 0.03% 72
2022
Q2 		$203K Hold
3,550
– – 0.06% 81
2022
Q1 		$217K Buy
+3,550
New +$184K 0.05% 81

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Cyrus J. Lawrence's ITCI Position: Q1 2025 in Review

Cyrus J. Lawrence sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 3,550 shares — an estimated $296K sold.

Cyrus J. Lawrence first reported a position in ITCI in Q1 2022 and held it in 11 quarters. The position peaked at $296K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Cyrus J. Lawrence reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Cyrus J. Lawrence sold 3,550 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $296K.
  • Cyrus J. Lawrence first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 11 quarters.
  • Cyrus J. Lawrence's Intra-Cellular Therapies Inc. position peaked at $296K in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Cyrus J. Lawrence's 13F filing for Q1 2025, filed 15 May 2025.